150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer

C Zhou,G Gao,L Wu,Z Wang,G Chen,D Huang,Z Yang,L Liu,H.Y Li

doi:10.1016/j.annonc.2021.10.169

150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer

C Zhou, G Gao + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.169

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
License type: publisher-specific-oa

Affiliation: Shanghai Pulmonary Hospital, Hunan Cancer Hospital, Shandong Tumor Hospital, Third Affiliated Hospital of Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, Guangdong Medical College, Luye Pharma (China), Lilly (China)

#Sintilimab In Combination #Metastatic Squamous Non-small Cell Lung + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Sintilimab in combination with gemcitabine and platinum-based chemotherapy has shown good efficacy in a randomized, double-blind, phase 3 study in Chinese patients with squamous NSCLC (ORIENT 12). This subgroup analysis assessed the efficacy of sintilimab combination stratified by key baseline patient characteristics (PD-L1 expression level and disease staging).

Full Text